AVAX Bites the Dust at $9.60: CME Hype Fizzles as Buyers Pass Out Before the Finish Line

AVAX put on quite the show on April 7, mooning 13.71% in under 18 hours—going from $8.46 to a glorious $9.62. The CME Group swooped in like a fairy godmother announcing they'd launch Avalanche Futures contracts in May, giving prices that sweet speculative boost. Throw in some broader market tailwinds for good measure, and suddenly everyone was posting rocket emojis. The vibes were immaculate, briefly.

But here's where things get spicy in a "that's not a knife, that's a butter knife" kind of way: Open Interest barely moved relative to that beefy 13% pump. Data revealed the first push toward $9.60 resistance came with a steeper OI climb, while the second rally since Monday screamed louder about sharp Spot CVD Uptick instead. During this whole fiesta, funding rates stayed stubbornly negative—meaning the longs holding bags weren't exactly getting rewarded with yield. Combine it all: speculative interest during the bounce was low-key nonexistent, but spot conviction was surprisingly firm. Still, even that spot conviction plus rising volume couldn't break through the $9.45–$9.60 supply zone. Turns out walls are still walls, even when you're hyped on hopium.

On the daily chart, the swing structure remains committed to its bearish storyline like a protagonist who refuses to have a redemption arc.